This post is an entry in The World
Isn’t Flat, It’s Parallel series running on nTersect, focused on the GPU’s
importance and the future of parallel processing. Today, GPUs can operate faster
and more cost-efficiently than CPUs in a range of increasingly important
sectors, such as medicine, national security, natural resources and emergency
services. For more information on GPUs and their applications, keep your eyes on
The
World Isn’t Flat, It’s Parallel.
Every time I hear about some little boy or girl who has a life-threatening
disease, I get reenergized to promote the opportunities that computers offer in
helping reduce disease and finding cures for human ailments. The exciting new
developments on this frontier have to do with using parallel computing to speed
up research and create the breakthrough discoveries that will save lives.
Finding new drugs is a complex and laborious task. Biochemists have to try
millions of compounds before they can figure out which ones are effective
against a particular virus or bacteria or which cause a desired reaction in the
human body. To narrow the field, scientists use automated tools for
high-throughput screening. But at some point, they have to test the remaining
biochemical compounds in time-consuming manual experiments in a “wet”
laboratory. (See our recent piece on the Tesla BioWorkbench for more information on how we’re helping
researchers in the life sciences use GPU computing in their work.)
Testing compounds is an iterative process, and it can take up to more than
five years before a new drug is finally discovered. Then there are five or more
years of clinical trials and so on as part of the FDA approval process.
Obviously, anything that can accelerate the testing process makes a significant
difference in the speed with which a potentially lifesaving new drug gets on the
market.
Computer simulations of biochemical reactions help point scientists in the
right direction and improve their productivity. The problem is, the computer
simulations necessary for this type of research are so compute-intensive they’re
typically done on supercomputers. It can take weeks or months on a supercomputer
to simulate just one biochemical reaction. For example, in order to simulate how
tiny cellular mechanisms called ribosomes work to build proteins out of amino
acids, it took scientists at Los Alamos National Laboratory more than eight
months of supercomputer time to recreate a process that in reality takes about 2 nanoseconds.
With about 15 million to 20 million researchers who could benefit from
supercomputer access and roughly a couple thousand supercomputers, there’s just
not enough computing resources to go around. Right now biochemists have to
request time on these supercomputers a year in advance, and not all researchers
even get access.
But if the right tools are available, scientists don’t have to wait to test
their new ideas. This is where parallel computing can accelerate innovation, by
removing the compute bottleneck represented by traditional supercomputers.
The tremendous parallel processing capability of GPUs accelerates
life-sciences applications by an order of magnitude. For example, a popular
molecular simulation applications called NAMD
(nanoscale molecular dynamics) gets the same performance out of four GPUs as it
does out of 16 CPUs. The speed-up is a result of the parallel architecture of
GPUs, which enables NAMD developers to port compute-intensive portions of the
application using the CUDA C toolkit.
The shift to parallel computing in the life sciences means that biochemists
can use a desktop Tesla Personal Supercomputer with four GPUs and
outperform a large cluster of CPU servers in a data center. If they need more
compute for their simulations, they can easily scale by using GPU-based clusters.
Scientists can thus augment their PCs and departmental servers with GPUs and
start doing large biomolecular simulations without requiring a supercomputer.
(Of course, GPUs are also being
added to the supercomputers soon.)
By giving scientists greater access to computing resources, GPU-based
computer simulations are helping to fulfill the promise of using computers to
accelerate the pace of drug discovery.